All In Biotech

Drug Trial Radar · NCT07235059

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

A Participant- and Investigator--Blinded, Placebo- Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Nov 20, 2025

Primary completion

Jan 21, 2028

Study completion Jan 21, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Conditions

  • Chronic Kidney Disease

Interventions

  • OJR520Drug

    Participants will receive OJR520 in different dose levels.

  • PlaceboOther

    Participants will receive OJR520 matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)Time frame: From Day 1 (Part A) until Day 71 (Part C)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Quotient Sciences Sea View

    Miami, Florida · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.